The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review

Journal of Clinical Lipidology

Volumn 3, Issue 2, 2009, Pages 85-93

  Reddy, Kota J ^a   Singh, Manmeet ^a   Bangit, Joey R ^a   Batsell, Richard R ^b  

^a Reddy Cardiac Wellness   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Darapladib; HDL C; Hepatitis C; Lp PLA2; Plaque rupture

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; BIOLOGICAL MARKER; DARAPLADIB; ENZYME INHIBITOR; EZETIMIBE; FLUINDOSTATIN; LIPID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STENOSIS; SYSTEMIC DISEASE; UNITED STATES;

HEPATITIS C VIRUS;

EID: 61949420869     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.01.004     Document Type: Review

References (47)

1. Atkinson Jr. A.J., Colburn W.A., and Degruttola V.G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Therapeut 69 (2001) 89-95
2. Casas J.P., Shah T., Cooper J., et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35 (2006) 922-931
3. Davey Smith G., Lawlor D.A., Harbord R., et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 25 (2005) 1051-1056 Erratum, 2005; 25:e129
4. Ridker P.M., Danielson E., Fonseca F.A., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
5. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49 (2007) 2003-2009
6. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
7. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5 (2008) e78
8. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary update 2005. Rev Esp Cardiol 58 (2005) 1062-1092
9. De Sutter J., De Bacquer D., Cuypers S., et al. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. Eur Heart J 26 (2005) 2644-2649
10. Kistorp C., Raymond I., Pedersen F., et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
11. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28 (2007) 1374-1381
12. Sarwar N., Sattar N., Gudnason V., and Danesh J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J 28 (2007) 2491-2497
13. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
14. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
15. Dada N., Kim N.W., and Wolfert R.L. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2 (2002) 17-22
16. Häkkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 2909-2917
17. Kolodgie FD, Burke AP, Taye A, et al. Lp-PLA2 is highly expressed in macrophages of coronary lesions prone to rupture. Presented at the Annual Scientific Session of the American Heart Association. New Orleans, LA, November 11, 2004.
18. MacPhee C.H., Moores K.E., Boyd H.F., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 (1999) 479-487
19. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J., and Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82 (2007) 159-165
20. Tsimikas S., Willeit J., Knoflach M., et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 30 (2009) 107-115
21. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
22. Koenig W., Khuseyinova N., Löwel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
23. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
24. Brilakis E.S., Joseph P., McConnell Jr. J.P., et al. Higher levels of lipoprotein-associated phospholipase A2 are associated with higher incidence of cardiovascular events at follow up independent of C-reactive protein. Eur Heart J 26 (2004) 137-144
25. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165 (2005) 2479-2484
26. Oei H.-H.S., Van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 166 (2005) 2073-2080
27. Elkind M.S., Tai W., Coates K., Paik M.C., and Sacco R.L. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166 (2006) 2073-2080
28. Robins S.J., Collins D., Nelson J.J., Bloomfield H.E., and Asztalos B.F. Lipoprotein-associated phospholipase A2, predicts cardiovascular events in the low HDL-C and low LDL-C population of Veterans Affairs HDL Intervention Trial (VA-HIT). Presented at European Society of Cardiology World Congress of Cardiology (September 2006), Spain, Barcelona Abstract 3448
29. Wassertheil-Smoller S., Kooperberg C., McGinn A.P., et al. Lipoprotein-associated phospholipase A2 and risk of ischemic stroke in postmenopausal women: The Women's Health Initiative Observational Study. Circulation 115 (2007) 657-e222
30. Wassertheil-Smoller S., Kooperberg C., McGinn A.P., et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 51 (2008) 1115-1122
31. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
32. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
33. Wolfert R.L., Kim N.W., Selby R.G., Sarno M.J., Warnick R.G., and Sudhir K. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk. Circulation 110 (2004) 309
34. Serruys P.W., Héctor M., García-García H.M., et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118 (2008) 1171-1182
35. Mohler III E.R., Ballantyne C.M., Davidson M.H., et al. Darapladib Investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51 (2008) 1642-1644
36. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
37. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
38. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752
39. Albert M.A., Glynn R.J., Wolfert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
40. Muhlestein J.B., May H.T., and Jensen J.R. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48 (2006) 396-401
41. Saougos V.G., Tambaki A.P., Kalogirou M., et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 27 (2007) 2236-2243
42. Kuvin J.T., Dave D.M., Sliney K.A., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745
43. Reddy R., Bangit J., Zaheer M., et al. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle counseling and combination lipid modifying drug therapy (2007), Presented at Scientific Sessions of the American Heart Association, Orlando, FL
44. Karabina S.A., Liapikos T.A., Grekas G., Goudevenos J., and Tselepis A.D. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1213 (1994) 34-38
45. Marathe G.K., Zimmerman G.A., and McIntyre T.M. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 278 (2003) 3937-3947
46. Guerra C.T., Caini P., Giannini C., et al. Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. Dig Liver Dis 39 suppl 1 (2007) S76-S82
47. Caini P., Guerra C.T., Giannini C., et al. Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. J Viral Hepat 14 (2007) 22-28